SCHEMBL5715233

SCHEMBL5715233

O=C(Oc1ccc(CCSc2ccccn2)cc1)N1CCN(c2ccc(F)cn2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 3/20 0.45
ME1 P48163 3/20 0.45
ME3 Q16798 3/20 0.45
HSD17B10 Q99714 5/20 0.44
ALDH1A1 P00352 4/20 0.44
TSHR P16473 3/20 0.44
CYP3A4 P08684 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C19 P33261 1/20 0.44
ALOX15 P16050 1/20 0.43
CHRM1 P11229 1/20 0.43
HPGD P15428 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PANK3 Q9H999 1/20 0.42
HRH3 Q9Y5N1 2/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714765 0.90 ALDH1A1 (0.55) HSD17B10ALDH1A1TSHRCYP3A4SMN1; SMN2
SCHEMBL5714531 0.89 TRPA1 (0.48) ME2ME1ME3HSD17B10ALDH1A1
SCHEMBL5714578 0.89 KDM4E (0.47) ME2ME1ME3HSD17B10ALDH1A1
SCHEMBL5714592 0.89 HTT (0.54) ALDH1A1SMN1; SMN2CHRM1HPGDL3MBTL1
SCHEMBL5714407 0.88 HSD17B10 (0.46) ME2ME1ME3HSD17B10ALDH1A1
SCHEMBL5714395 0.88 HSD17B10 (0.46) ME2ME1ME3HSD17B10ALDH1A1
SCHEMBL5714729 0.86 ME2 (0.46) ME2ME1ME3ALDH1A1SMN1; SMN2
SCHEMBL5715291 0.84 ME2 (0.48) ME2ME1ME3HSD17B10ALDH1A1
SCHEMBL5715128 0.84 ME2 (0.43) ME2ME1ME3SMN1; SMN2ALOX15
SCHEMBL5715416 0.83 ME2 (0.43) ME2ME1ME3ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC ME2 854/4885ME1 2914/4885ME3 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.